title: Long-term prognosis of esophageal variceal cases treated with injection sclerotherapy.
abstract: One hundred fifty-two patients with esophageal varices underwent a total of 485 injection sclerotherapy procedures (mean, 3.2 times per each case). During 5 years of observation, 20 cases (13.2%) died following injection sclerotherapy. The 3-year survival rates, based on the Kaplan-Meier method, were 42% for emergency cases, 75% for elective cases and 90% for prophylactic cases. Significant differences (P less than 0.05) by the generalized Wilcoxon test were observed in the survival rates between emergency cases and prophylactic cases, and also between elective cases and prophylactic cases. Two cases (8.6%) of failure to control acute hemostasis were experienced. Twenty cases of bleeding after sclerotherapy were experienced, and 8 died of bleeding. The three-year bleeding rate according to the Kaplan-Meier method was 59% for emergency cases, 25% for elective cases and 7% for prophylactic cases. A significant difference (P less than 0.05) by the generalized Wilcoxon test was observed in the bleeding rate between elective cases and prophylactic cases. Non-bleeding rate (100%-bleeding rate) after sclerotherapy showed almost the same values as the survival rate. These results indicate that upper digestive tract hemorrhage influences the prognosis of patients after sclerotherapy.
authors: Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Japan.
authors: H
authors: H
authors: Miyoshi
authors: H
authors: H
authors: Tei
authors: K
authors: K
authors: Ashida
authors: N
authors: N
authors: Osaka
authors: A
authors: A
authors: Matsumoto
authors: I
authors: I
authors: Hirata
authors: S
authors: S
authors: Ohshiba
mesh_terms: D000328:Adult; D000368:Aged; D004066:Digestive System Diseases / Q000209:etiology; D004932:Esophageal and Gastric Varices / Q000401:mortality / Q000628:therapy*; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007267:Injections; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D015911:Sclerotherapy / Q000009:adverse effects; D013997:Time Factors